Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.

David S Hong Michael A Postow Bartosz Chmielowski Ryan J Sullivan Amita Patnaik Ezra E W Cohen Geoffrey I Shapiro Conor E Steuer Martin Gutierrez Heather Yeckes-Rodin Robert Ilaria Brenda C O'Connell Joanna Peng Guangbin Peng Nora Zizlsperger Anthony W Tolcher Jedd D Wolchok

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Based on the observed safety profile, eganelisib doses of 30 mg and 40 mg once daily in combination with PD-1/PD-L1 inhibitors were chosen for phase 2 study.

Keyphrases

open label
phase iii
study protocol
phase ii
clinical trial
double blind
placebo controlled
randomized controlled trial